The Clinical Relevance of Antifibrillarin (anti-U3-RNP) Autoantibodies in Systemic Sclerosis
Autor: | J. Cabane, E Ballot, Y Chantran, Nicole Fabien, J. Ninet, D. Jullien, F. Tall, P. Chretien, M. Dechomet, K. P. Tiev, V. Cottin, Catherine Johanet, C. Grange, Sébastien Rivière, R. Montin, C. Morin |
---|---|
Rok vydání: | 2016 |
Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty Chromosomal Proteins Non-Histone Immunology medicine.disease_cause Gastroenterology Scleroderma Autoimmunity Cell Line 03 medical and health sciences 0302 clinical medicine Ribonucleoproteins Small Nucleolar Internal medicine parasitic diseases medicine Ethnicity Prevalence Humans Clinical significance Myositis Survival analysis Autoantibodies Retrospective Studies 030203 arthritis & rheumatology Autoimmune disease Scleroderma Systemic business.industry Autoantibody Retrospective cohort study General Medicine Middle Aged medicine.disease Survival Analysis 030104 developmental biology Female France business |
Zdroj: | Scandinavian journal of immunology. 85(1) |
ISSN: | 1365-3083 |
Popis: | Objectives Systemic sclerosis (SSc) is a heterogeneous autoimmune disease associated with several antinuclear autoantibodies useful to diagnosis and prognosis. The aim of the present multicentric study was to determine the clinical relevance of anti-fibrillarin autoantibodies (AFA) in patients with SSc. Methods The clinical features of 37 SSc patients positive for AFA (AFA+) and 139 SSc patients without AFA (AFA-) were collected retrospectively from medical records to enable a comparison between AFA- and AFA+ patients. Anti-fibrillarin autoantibodies were screened by an indirect immunofluorescence technique using HEp2 cells and identified by an in-house Western blot technique and/or an EliA test. Results Comparing AFA+ and AFA– patients, AFA+ patients were significantly younger at disease onset (36.9 vs. 42.9; p=0.02), more frequently male (p=0.02) and of Afro-Caribbean descent (65% vs. 7.7%; p |
Databáze: | OpenAIRE |
Externí odkaz: |